LIL-HM14D-100μg / 询价
LIL-HM14D-500μg / 询价
LIL-HM14D-500μgx2 / 询价
Human LILRB4/CD85k/ILT3 Domain1&2 Protein
Recombinant Human LILRB4/CD85k/ILT3 Domain1&2 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Pro27-Ser218 [Accession | AAH26309].
The protein has a predicted MW of 22.9 kDa. Due to glycosylation, the protein migrates to 23-25 kDa based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
> 95% as determined by HPLC
Less than 1EU per μg by the LAL method.
Supplied as 0.22μm filtered solution in 20mM Tris, 150mM NaCl (pH 8.2).
Valid for 12 months from date of receipt when stored at -80°C.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Human LILRB4 Domain1&2 on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Human LILRB4 Domain1&2 is greater than 95% as determined by SEC-HPLC.
Immobilized Human LILRB4 Domain 1&2, His Tag at 2μg/ml (100μl/Well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 18.2ng/ml determined by ELISA.
LILRB4,also known as CD85k and LIR-5, ILT3, is an approximately 60 kDa transmembrane glycoprotein that negatively regulates immune cell activation. Mature human ILT3 consists of a 238 amino acid (aa) extracellular domain with two Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 3 immunoreceptor tyrosine-based inhibitory motifs (ITIM).LILRB4 is receptor for class I MHC antigens. Recognizes a broad spectrum of HLA-A, HLA-B, HLA-C and HLA-G alleles.
HM18; ILT3; ILT-3; LILRB4; LIR5; CD85K
(1)Samuel J , Heyu C , Mi D , et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML[J]. Molecular Therapy, 2018:S1525001618303721-.
